Express Pharma
Home  »  Latest Updates  »  DRL announces launch of Raloxifene HCl Tablets in the US market

DRL announces launch of Raloxifene HCl Tablets in the US market

11

DRL’s tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000

Dr Reddy’s Laboratories has launched of Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the US Food & Drug Administration (US FDA).

The Evista brand and generic had US sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*

Dr Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

EP News Bureau

Comments are closed.